Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III Trial
Yuan Zhang(Sun Yat-sen University), Ling‐Long Tang(Sun Yat-sen University), Ying‐Qin Li(Sun Yat-sen University), Yu‐Pei Chen(Sun Yat-sen University), Mei Shi(Xijing Hospital), Xiaojing Du(Sun Yat-sen University), Ye Tian(Soochow University), Guoxian Long(Tongji Hospital), Qiong-Fei Su(First Affiliated Hospital of Guangdong Pharmaceutical University), Zhibin Cheng(L-3 Communications (United States)), Guan‐Qun Zhou(Sun Yat-sen University), Hao‐Yuan Mo(L-3 Communications (United States)), Qiaodan Liu(L-3 Communications (United States)), Ying Sun(Qilu Hospital of Shandong University), Yan Sun(Union Hospital), Feng Jin(China Medical University), Jing Huang(Jilin University), Li Zou(Sun Yat-sen University), Kunyu Yang(Union Hospital), Cheng Xu(Pennsylvania State University), Fei Han(Tianjin Medical University), Yan‐Ping Mao(Sun Yat-sen University), Xu Liu(Sun Yat-sen University), Lei Chen(Cincinnati Children's Hospital Medical Center), Yuhong Li(Sun Yat-sen University), Na Liu(Sun Yat-sen University), Ning Zhang(First People's Hospital of Foshan), Jun Ma(Shanghai Jiao Tong University), Ling Li(Guangxi Medical University), Xiao‐Dong Zhu(Guangxi Medical University), Rui Guo(Sun Yat-sen University), Siyang Wang(L-3 Communications (United States)), Wei‐Han Hu(Sun Yat-sen University), Guoqing Hu(Tongji Hospital), Jinhua Long(Guizhou Cancer Hospital), Xicheng Wang(First Affiliated Hospital of Guangdong Pharmaceutical University), Jia‐Wei Lv(Zhejiang Chinese Medical University), Shaoqiang Liang(First People's Hospital of Foshan), Jingao Li(Jiangxi Provincial Cancer Hospital), Wen‐Fei Li(Sun Yat-sen University), Jian Zang(Xijing Hospital), Rui Sun(Sun Yat-sen University), Baomin Zheng(Peking University), Yun Xiao(Chongqing Medical University), Ying Guo(Sun Yat-sen University), Fang‐Yun Xie(Sun Yat-sen University)
Cited by 147
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934